NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company focused on developing and producing therapeutic radioisotopes and radiopharmaceuticals for cancer detection and treatment. Its work centers on non-reactor-based production methods, a key differentiator in an industry historically reliant on nuclear reactors for isotope supply.
The company's technical capabilities span radiopharmaceutical production, electron accelerator technology, targeted alpha therapy, and radioisotope manufacturing. Its product pipeline includes Actinium-225 (Ac-225) and Copper-67 (Cu-67), both therapeutic radioisotopes intended for use in targeted alpha therapy for cancer. These are produced using proprietary processes that avoid traditional reactor-based supply chains.
NorthStar operates in the radiopharmaceuticals, cancer treatment, and medical isotope production sectors, and also offers contract development and manufacturing (CDMO/CMO) services. The company is based in Beloit, Wisconsin.
